Research Article

Expression of RRBP1 in epithelial ovarian cancer and its clinical significance

Jing Ma*, Sujing Ren*, Jing Ding, Shuang Liu, Jiaqi Zhu, Rong Ma and Fanling Meng

Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, China

Correspondence: Fanling Meng (dr_mfl1979@126.com) or Rong Ma (dr_marong2017@126.com)

Hematopoietic pre-B cell leukemia transcription factor (PBX)-interacting protein (RRBP1) has been shown to participate in various aspects of malignancies. The clinical significance of RRBP1 and its involvement in the epithelial ovarian cancer have yet to be studied. The aim of the present study was to investigate the expression of RRBP1 in epithelial ovarian cancer (EOC) and its relationship with clinical characteristics and prognosis. We evaluated the mRNA and protein expression levels of RRBP1 by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting (n=45). Immunohistochemistry and data analysis were used to examine the relationship between the expression level of RRBP1 and the clinicopathological features and prognosis of epithelial ovarian cancer. RRBP1 was highly expressed in EOC (P<0.001). The specimens were obtained from 108 patients undergoing surgery to treat epithelial ovarian cancer. RRBP1 expression was obviously related to Federation International of Gynecologie and Obstetrique (FIGO) stage (P<0.001), histological grade (P=0.021), histological type (P=0.004), and lymph node metastasis (P=0.012) but was not related to patient age (P=0.385) or preoperative carbohydrate antigen125 (CA125) level (P=0.238). Univariate analysis showed that the prognosis of the epithelial ovarian cancer patients was related to the age of the patients, the FIGO stage, and the expression level of RRBP1 (P<0.05). Patients with higher RRBP1 expression had significantly worse overall survival (OS) (P=0.003) and disease-free survival (DFS) (P<0.001). Multivariate survival analysis proved that RRBP1 was an independent predictor of OS (P=0.003) and DFS (P<0.001). RRBP1 plays an important role in predicting the prognosis of EOC. These results show that RRBP1 is a potential target for the treatment of epithelial ovarian cancer.

Introduction

Ovarian cancer is one of the most deadly gynecological tumors [1]. It is characterized by a lack of early clinical symptoms, and it is often detected at the last stage [2,3]. Although most patients initially respond to surgical debulking and chemotherapy, [4] the 5-year survival rate for ovarian cancer patients is only 20–40%; these low rates are mainly due to the occurrence of metastasis and recurrence [5]. Patients whose cancer is detected and treated in the early stages of the disease have significantly higher survival rates than those whose cancer is detected in the later stages; the survival rates for the former group can exceed 90% [6]. Therefore, further study on the identification of novel markers that can help detect tumor occurrence and metastasis is important for examining the development and treatment of ovarian cancer.

Hematopoietic pre-B cell leukemia transcription factor (PBX)-interacting protein (RRBP1) is an amino acid protein consisting of a hydrophobic NH2-terminus that includes a membrane-binding domain, a ribosome-binding domain, and an acidic coiled-coil COOH-terminal domain. RRBP1 is mainly located in the endoplasmic reticulum (ER), where it plays an important role in the intracellular transport of proteins in mammalian cells and participates in the secretion of proteins [7–10].
Figure 1. RRBP1 protein expression in EOCs by Western blot
(A) Representative protein samples obtained from frozen normal epithelial ovarian tissues (N) and epithelial ovarian cancer tissues (T) were analyzed by Western blot. The levels of β-actin were used as an internal control; (B) Histogram of pooled data from N (n=16) and EOCs (n=29). RRBP1 expression was elevated in EOCs compared with that in N. The data are presented as the mean ± s. d. (***P<0.05).

Studies in yeast have shown that RRBP1 also plays a role in ER stress and the associated unfolded protein response (UPR) [11,12]. In addition, RRBP1 stabilizes mRNA in yeast, but its mediated stabilization does not depend on the UPR [13]. It has been reported that RRBP1 also binds to the kinesis protein KF15B, which is highly expressed in several cancer cell lines [14]. Recently, RRBP1 has been found to have a higher frequency of overexpression in colorectal cancer, [15,16] lung cancer, [17], and breast cancer [18,19]. Additionally, RRBP1 has become a potential marker of poor prognosis in colorectal cancer and breast cancer. Moreover, there are already data showing that RRBP1 plays an important role in the survival of tumor cells, the maintenance of malignant tumors and the adaptation of ER stress [15,20]. Therefore, it is very valuable to explore the impact of RRBP1 on the diagnosis and prognosis of ovarian cancer. Further verification of the possibility of RRBP1 as an independent tumor biomarker is also necessary for epithelial ovarian cancer.

In the present study, the clinicopathological effects of RRBP1 in epithelial ovarian cancer and their association with prognosis were analyzed and validated.

Materials and methods
Patients and treatment
In the present study, we examined 108 tumor specimens for immunohistochemistry. Specimens were obtained from patients with epithelial ovarian cancers at the Department of Gynecology of the the Harbin Medical University Cancer Hospital from February 2010 to June 2013. Tumor specimens were collected during surgery. None of the patients underwent relevant cancer treatment before surgery. The first operation of the patient aims to achieve maximum resection of the tumor, and a standard chemotherapy regimen of carboplatin plus paclitaxel is given postoperatively.

The patients’ ages ranged from 35 to 75, and the median age was 55 years. The follow-up period for patients was April 2018, the follow-up time was between 1 and 96 months, and the median follow-up time was 48 months. All clinical information to be studied is summarized and listed in Table 1. The normal samples in the present study were selected from 16 women undergoing hysterectomy for hysteromyoma at the Department of Gynecology of the Harbin Medical University Cancer Hospital.

The institutional ethics committee approval for the project was obtained from the Medical Ethics Committee of The Affiliated Tumor Hospital of Harbin Medical University before the study was started, and informed consent was obtained from each patient.

Western blot analysis
Forty-five samples were frozen in liquid nitrogen. The lysate was mixed proportionally with a protease inhibitor and used to cleave the extracted protein. The BCA method was then used to determine the protein concentration in the sample solution. The protein separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis was immediately transferred to a polyvinylidene fluoride membrane. After the transfer, a 5% skim milk powder solution was placed and sealed at room temperature. The primary antibodies against RRBP1 (1:500, Abcam, Anti-RRBP1 antibody ab95983) and β-actin (Santa Cruz Biotechnology, Santa Cruz, CA) were then diluted with a 5% skim milk
Figure 2. RRBP1 expression in EOCs by immunohistochemistry

Immunohistochemical staining of RRBP1 in EOC specimens: (A, B) High expression of RRBP1 in EOCs; (C, D) Low expression of RRBP1 in EOCs.

Real-time PCR

The expression of RRBP1 mRNA was quantified by RT-PCR. Forty-five samples were used for real-time PCR, including twenty-nine epithelial ovarian cancer samples and sixteen normal tissue samples. Total RNA was isolated using an TRNzol reagent (BioTeke, Beijing, China). The concentration of RNA in each sample was determined using an ultraviolet spectrophotometer NANO 2000. The RNA sample obtained above was subjected to reverse transcription to obtain a corresponding cDNA. This step was done by the RCR instrument. Primers for RRBP1: Forward, 5′-AACCTAATGGGAAGATACCTGA-3′; Reverse, 5′-CATGGCTGGAACTGTGGC-3′. The primer sequence for β-actin as a reference is: Forward, 5′-CGGGAAATCGTGCGTGAC-3′; Reverse, 5′-GTCAGGCAGCTCGTAGCTCTT-3′. In this experiment, fluorescence quantitative analysis was performed using an ExicyclerTM 96 fluorescence meter (BIONEER, Korea). Relative RRBP1 abundances were determined with the $2^{-\Delta\Delta C_t}$ method. This experiment was repeated three times.

Immunohistochemical staining

Epithelial ovarian cancer tissue was cut into 4-micron-thick serial sections, fixed in formalin and embedded in paraffin. These paraffin sections were baked at 65°C for 30 min. To deparaffinize and rehydrate, the slides were placed in hydrogen peroxide (concentration 3%). All slides were immersed in 0.01 mol/l EDTA, autoclaved at 121°C for 4 min, cooled to room temperature, immersed three times with distilled water for 2 min, and washed three times with PBS for 5 min. Anti-RRBP1 antibody (Abcam, Anti-RRBP1 antibody ab95983) was used overnight at 4°C at a 1:400 dilution. The antibody was then immobilized three times with PBS for 5 min, placed into the moisture box, supplemented with the secondary antibody, and then placed in the humidor for 20 min at room temperature. The slides were counterstained with Hematoxylin, dehydrated, sealed, and placed in an oven at 60°C for 48 h.
Table 1 Association analyses between the expression levels of RRBP1 and the clinicopathological characteristics of epithelial ovarian cancer (EOC)

| Variables                  | Patients | RRBP1 expression | P          |
|----------------------------|----------|------------------|------------|
|                            | n        | Low Moderate High|            |
| All cases                  |          |                  |            |
| Age (years)                |          |                  |            |
| ≤55                        | 61       | 7 10 44          | P=0.385    |
| >55                        | 47       | 4 4 39           |            |
| FIGO stage                 |          |                  |            |
| I                          | 9        | 8 1 0            | P<0.001    |
| II                         | 14       | 1 11 2           |            |
| III                        | 80       | 2 2 76           |            |
| IV                         | 5        | 0 0 5            |            |
| Histological grade         |          |                  |            |
| G1                         | 14       | 4 3 7            | P=0.021    |
| G2/G3                      | 94       | 7 11 76          |            |
| Histological type          |          |                  |            |
| Serous                     | 91       | 5 10 76          | P=0.004    |
| Mucinous                   | 7        | 2 2 3            |            |
| Endometrioid               | 6        | 2 1 3            |            |
| Clear cell                 | 4        | 2 1 1            |            |
| CA125 (U.ml⁻¹)             |          |                  |            |
| ≤35                        | 7        | 2 1 4            | P=0.238    |
| >35                        | 101      | 9 13 79          |            |
| Lymph node metastasis      |          |                  |            |
| No                         | 85       | 11 14 60         | P=0.012    |
| Yes                        | 23       | 0 0 23           |            |

Abbreviations: CA125, carbohydrate antigen125; EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; RRBP1, Hematopoietic pre-B cell leukemia transcription factor (PBX)-interacting protein. ¹χ² test.

Staining assessment and scoring

The RRBP1 immunohistochemical expression score was scored using a semiquantitative method. Based on the number of positive tumor cells, the staining was scored as follows: level 0 (<10%), level 1 (10–33%), level 2 (34–66%), and level 3 (67–100%). The staining intensity was rated as 0–3 points according to negative, weak, moderate and strong staining. The final score is the sum of the two indicators.

In all samples, 0–1 was considered low expression, 2–3 was considered moderate expression, and >3 was considered high expression.

Statistical analysis

The difference in RRBP1 expression between epithelial ovarian cancer tissues and normal tissues was evaluated by Western blotting and quantitative real-time polymerase chain reaction (qRT-PCR). The relationship between the level of RRBP1 expression and the different clinicopathological factors was analyzed using the χ² test. The correlation between the survival of patients with epithelial ovarian cancer and the level of RRBP1 expression was depicted and analyzed using the Kaplan–Meier method. At the same time, the impact of various clinical factors on the prognosis of epithelial ovarian cancer patients was analyzed by the log-rank test. A Cox regression model was performed for multivariate analysis of independent prognostic factors. Statistical significance was defined as P<0.05. All statistical analyses were carried out using the statistical software package SPSS V21.0.0.

Results

RRBP1 expression in patients with epithelial ovarian cancer

The difference in RRBP1 expression between epithelial ovarian cancer tissues and normal tissues was evaluated by Western blotting experiments and Real-time PCR. Western blotting results showed the expression of RRBP1 was excessive at protein level in epithelial ovarian cancer samples (P<0.05, Figure 1). Real-time PCR results showed that the
expression of RRBP1 at mRNA level in epithelial ovarian cancer tissues is much higher than that in normal epithelial ovarian cancer tissues ($P<0.05$, Figure 3).

**RRBP1 expression is associated with clinicopathological feature in epithelial ovarian cancer**

The expression of RRBP1 in epithelial ovarian cancer tissues was analyzed by immunohistochemistry. Results of immunohistochemical staining are shown in Figure 2A–D. In the 108 epithelial ovarian cancer specimens, statistical analysis showed that 77% of cases had high expression, 13% of cases had moderate expression, and 10% had low expression. Moreover, the high RRBP1 expression in epithelial ovarian cancer was closely related to Federation International of Gynecologie and Obstetrique (FIGO) stage ($P<0.001$), histological grade ($P=0.021$), histological type ($P=0.004$), and lymph node metastasis ($P=0.012$). High RRBP1 expression was not related to age ($P=0.0385$) or preoperative carbohydrate antigen125 (CA125) value ($P=0.238$). All statistical results are tabulated and summarized in Table 1.

**The influence of RRBP1 expression on the survival of patients with epithelial ovarian cancer**

Just as the Kaplan–Meier analysis shows, the high expression of RRBP1 significantly affects the overall survival (OS) or disease-free survival (DFS) of patients (Figure 4A,B; Table 2. $P=0.003$ and $P<0.001$, respectively). Moreover, the univariate survival analysis found that the patient age and the pathological type are also related to the prognosis of the patient (Table 2, all $P<0.05$).

**Independence of RRBP1 expression from other clinicopathological factors**

To assess whether the prognosis prediction ability of RRBP1 expression is independent of other clinicopathological features of patients with epithelial ovarian cancer, we performed multivariate Cox regression analysis. The data show that RRBP1 is an independent prognostic factor for both OS (Table 3, confidence interval [CI] = 1.346–4.102, $P=0.003$) and DFS (Table 3, CI = 1.554–3.709, $P<0.001$) in patients with epithelial ovarian cancer.

**Discussion**

In the present study, we examined the expression level of RRBP1 in epithelial ovarian cancer by immunohistochemical experiments involving 108 epithelial ovarian cancer samples. At the same time, we selected 29 cases of cancer tissue specimens and 16 normal tissue specimens for Western blotting and qRT-PCR to study the expression of RRBP1 at
Figure 4. Kaplan–Meier analysis of OS and DFS related to the expression of RRBP1
Patients with high expression of RRBP1 had a poorer prognosis than those with low expression of RRBP1. (A) OS curves of the EOC according to their RRBP1 expression status, $P=0.003$; (B) DFS curves of the EOC patients according to their RRBP1 expression status, $P<0.001$. 

© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
have found that RRBP1 plays an important role in the prognosis of tumors. The role of RRBP1 in epithelial ovarian cancer.

To our knowledge, this is the first examination to demonstrate the overexpression of RRBP1 in epithelial ovarian cancer and to suggest that RRBP1 may be a valuable prognostic biomarker for epithelial ovarian cancer. The findings indicate that RRBP1 plays an important role in the progression of epithelial ovarian cancer and that it has a profound effect on the prognosis of epithelial ovarian cancer. These findings confirmed that expression of RRBP1 in epithelial ovarian cancer tissues was much higher than that in normal tissues. Overexpression of RRBP1 in epithelial ovarian cancer was shown to be obviously related to FIGO stage, histological grade, histological type, and lymph node metastasis. In addition, our data showed that epithelial ovarian cancer patients with RRBP1 overexpression had significantly decreased OS and DFS. RRBP1 is an independent prognostic factor for epithelial ovarian cancer. These findings indicate that RRBP1 plays an important role in the progression of epithelial ovarian cancer and that it has a profound effect on the prognosis of epithelial ovarian cancer. To our knowledge, this is the first examination to demonstrate the overexpression of RRBP1 in epithelial ovarian cancer and to suggest that RRBP1 may be a valuable prognostic biomarker for epithelial ovarian cancer.

Earlier research reports on RRBP1 in tumors, including breast cancer, [18,19] lung cancer, [17] and colorectal cancer, [15,16] have found that RRBP1 plays an important role in the prognosis of tumors. The role of RRBP1 in

**Table 2 Univariate survival analysis of OS and DFS in 108 patients with EOC**

| Variables                   | OS          | DFS          |
|-----------------------------|-------------|--------------|
|                            | n           | Mean ± SE (month) | 95% CI |       | n           | Mean ± SE (month) | 95% CI |
| Age ≤55                     | 61          | 60 ± 5       | 51–69   | P = 0.026 | 40 ± 5 | 31–49 | P = 0.045 |
| >55                         | 47          | 42 ± 5       | 42–52   | P = 0.004 | 69 ± 12 | 46–92 | P = 0.001 |
| FIGO stage                  |             |              |         |         |             |              |         |
| I                           | 9           | 82 ± 10      | 62–103  | P = 0.004 | 69 ± 12 | 46–92 | P = 0.001 |
| II                          | 14          | 75 ± 8       | 59–91   | P = 0.004 | 56 ± 9 | 38–73 | P = 0.001 |
| III                         | 80          | 45 ± 4       | 36–52   | P = 0.004 | 27 ± 3 | 21–32 | P = 0.001 |
| IV                          | 5           | 34 ± 11      | 13–56   | P = 0.004 | 26 ± 9 | 9–43  | P = 0.001 |
| Histological grade          |             |              |         |         |             |              |         |
| G1                          | 14          | 64 ± 9       | 46–82   | P = 0.361 | 49 ± 9 | 31–68 | P = 0.127 |
| G2/G3                       | 94          | 50 ± 4       | 43–58   | P = 0.361 | 31 ± 3 | 25–37 | P = 0.706 |
| Histological type           |             |              |         |         |             |              |         |
| Serous                      | 91          | 54 ± 4       | 46–61   | P = 0.358 | 34 ± 2 | 27–40 | P = 0.706 |
| Mucinous                    | 7           | 39 ± 14      | 11–67   | P = 0.358 | 33 ± 13 | 6–59 | P = 0.706 |
| Endometrioid                | 6           | 50 ± 15      | 21–80   | P = 0.358 | 34 ± 11 | 12–55 | P = 0.706 |
| Clear cell                  | 4           | 31 ± 12      | 8–54    | P = 0.358 | 29 ± 10 | 1–39  | P = 0.706 |
| CA125 (U·ml⁻¹) ≤35          | 7           | 44 ± 11      | 23–65   | P = 0.654 | 31 ± 12 | 8–55  | P = 0.777 |
| >35                         | 101         | 53 ± 4       | 46–60   | P = 0.654 | 35 ± 3 | 28–41 | P = 0.777 |
| Lymph node metastasis       |             |              |         |         |             |              |         |
| No                          | 85          | 53 ± 4       | 45–61   | P = 0.785 | 37 ± 4 | 30–45 | P = 0.118 |
| Yes                         | 23          | 50 ± 7       | 37–64   | P = 0.785 | 24 ± 4 | 16–33 | P = 0.118 |
| RRBP1 Low expression        | 11          | 84 ± 9       | 66–103  | P = 0.003 | 74 ± 10 | 53–94 | P = 0.000 |
| Moderate expression         | 14          | 66 ± 8       | 50–82   | P = 0.003 | 51 ± 9 | 33–70 | P = 0.000 |
| High expression             | 83          | 45 ± 4       | 38–52   | P = 0.003 | 25 ± 3 | 20–31 | P = 0.003 |

*Abbreviations: CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; RRBP1, Hematopoietic pre-B cell leukemia transcription factor (PBX)-interacting protein. Log-rank test.*

**Table 3 Multivariate survival analysis of OS and DFS in 108 patients with EOC**

| Variables       | Exp (B) | 95% CI        | P¹ | Exp (B) | 95% CI        | P¹ |
|-----------------|---------|---------------|----|---------|---------------|----|
| FIGO stage      | 1.408   | 0.718–2.761   | P = 0.320 | 0.971 | 0.538–1.753 | P = 0.922 |
| RRBP1           | 2.350   | 1.346–4.102   | P = 0.003 | 2.397 | 1.554–3.790 | P < 0.001 |
| Age             | 1.587   | 0.987–2.551   | P = 0.057 | 2.427 | 1.418–9.065 | P = 0.072 |

*Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; RRBP1, hematopoietic pre-B cell leukemia transcription factor (PBX)-interacting protein; CI, confidence interval. Cox regression test.*
epithelial ovarian cancer was consistent with the results of the current study and proved the connection between the overexpression of RRBP1 in epithelial ovarian cancer and adverse biological behavior. These findings suggest that RRBP1 plays an important biological role in the development of cancer and tumor progression. The above results improve the possibility that RRBP1 may be a prognostic parameter of ovarian cancer, suggesting that RRBP1 can be used for individualized treatment and prognostic evaluation in patients with epithelial ovarian cancer.

Many studies have explained the mechanism by which RRBP1 promotes the development of cancer. IMT study by Lee et al. [21] provides the first proof of the mechanism of recurrent carcinogenesis in RRBP1-ALK. The results of the study by Nazarian et al. [10] showed that the expression of RRBP1 regulates RNA stability by localizing the ER membrane at the mRNA conversion level rather than at the transcriptional level, which may be achieved by locating mRNA on the ER membrane and protecting it from cell cycle-dependent degradation. Tsai et al. [17] found that the carcinogenic mechanism of RRBP1 is related to the UPR pathway and that RRBP1 may attenuate ER stress and help tumors survive tumorigenesis. Their findings also suggested that RRBP1 may participate in the accumulation of perinuclear autophagosomes in cancer cells by interacting with the kinesin family member 5B (KIF5B) [16]. During tumorigenesis, adaptive stress responses cause UPRs and initiate the activation of survival cascade mechanisms. In some reports, the increase in RRBP1 protein expression in tumor cells is attributed to increased RRBP1 mRNA due to gene amplification and/or elevated transcription [16,18]. Gao et al. [22] studied the regulation of RRBP1 at the translation level and found that La autoantigen induced RRBP1 expression under cellular stress through the internal ribosomal entry site (IRES). The current research report further proves that RRBP1 participates in and promotes the occurrence and development of cancer, but the specific mechanism of action has yet to be elucidated and warrants further research.

The significance of RRBP1 cancer research is to use the gene as a potential target for cancer therapy. Research results have shown that RRBP1 knockdown can affect the stability of ATF6 and GRP78 mRNA, thereby reducing the in vivo tumorigenicity of lung cancer cells [17]. Studies have shown that UTR-induced trastuzumab resistance may be a cause of poor prognosis in patients with RRBP1 expression [19]. The above studies indicate the possibility of RRBP1 as a new idea for curing epithelial ovarian cancer. Of course, basic research needs further support.

Conclusions
In summary, RRBP1 is overexpression in most epithelial ovarian cancer patients, and overexpression of RRBP1 in epithelial ovarian cancer leads to an even worse prognosis in patients with epithelial ovarian cancer. However, to effectively apply the effect of RRBP1 in tumors to the curing of tumors, it needs to do more accurate experiments are needed to verify this hypothesis.

Availability of data and materials
The data used and analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgments
We express our thanks to Dr. Yanyan Wang for the evaluation procedures.

Author Contribution
J.M.: data acquisition and manuscript writing, S.J.R.: quality control of data and manuscript review, J.D., S.L., and J.Q.Z.: follow-up and quality control of data, F.L.M. and R.M.: study concept and design.

Competing Interests
The authors declare that there are no competing interests associated with the manuscript.

Consent for publication
Informed consent was obtained from all participants for publication.

Ethics approval and consent to participate
The present study was approved by the Medical Ethics Committee of The Affiliated Tumor Hospital of Harbin Medical University. All procedures were performed by the ethical standards of our institutional research committee. Written informed consent was obtained from each participant by the institutional guidelines.
Funding
This work was supported by grants of the Liande Wu Science Foundation for Young Scholars of Harbin Medical University Cancer Hospital [grant number WLD-QN1705]. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Abbreviations
CA125, carbohydrate antigen125; CI, confidence interval; DFS, disease-free survival; EOC, epithelial ovarian cancer; ER, endoplasmic reticulum; FIGO, Federation International of Gynecologie and Obstetrique; OS, overall survival; qRT-PCR, quantitative real-time polymerase chain reaction; RRBP1, Hematopoietic pre-B cell leukemia transcription factor (PBX)-interacting protein; UPR, unfolded protein response.

References
1. Chen, W., Zheng, R., Baade, P.D. et al. (2016) Cancer statistics in China, 2015. CA Cancer J. Clin. 66, 115–132. https://doi.org/10.3322/caac.21338
2. Sato, S., Kato, T., Abe, K. et al. (2017) Erratum: pre-operative evaluation of circulating KL-6 levels as a biomarker for epithelial ovarian carcinoma and its correlation with tumor MUC1 expression. Oncol. Lett. 14, 5051, https://doi.org/10.3892/ol.2017.6148
3. Qu, Y., Cong, P., Lin, C. et al. (2017) Inhibition of paclitaxel resistance and apoptosis induction by cucurbitacin B in ovarian carcinoma cells. Oncol. Lett. 14, 145–152, https://doi.org/10.3892/ol.2017.6148
4. Do, T.V., Hirst, J., Hyter, S. et al. (2017) Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells. Oncotarget 8, 50376–50392, https://doi.org/10.18632/oncotarget.18970
5. Sun, X., Zhang, W., Li, H. et al. (2017) Storni 2 overexpression is correlated with unfavorable prognosis and tumor invasion in epithelial ovarian cancer. Int. J. Mol. Sci. 18, pii: E1653, https://doi.org/10.3390/ijms18081653
6. Luo, P., Liu, X.F., Wang, Y.C. et al. (2017) Prognostic value of abnormally expressed IncRNAs in ovarian carcinoma: a systematic review and meta-analysis. Oncotarget 8, 23927–23936
7. Bai, J.Z., Leung, E., Holloway, H. et al. (2008) Alternatively spliced forms of the P180 ribosome receptor differ in their ability to induce the proliferation of rough endoplasmic reticulum. Cell Biol. Int. 32, 473–483, https://doi.org/10.1016/j.cellbi.2007.10.002
8. Benyamini, P., Webster, P. and Meyer, D.I. (2009) Knockdown of p180 eliminates the terminal differentiation of a secretory cell line. Mol. Biol. Cell 20, 732–744, https://doi.org/10.1091/mbc.e08-07-0682
9. Ueno, T., Tanaka, K., Kanioka, K. et al. (2010) Enhancement of procollagen biosynthesis by p180 through augmented ribosome association on the endoplasmic reticulum in response to stimulated secretion. J. Biol. Chem. 285, 29941–29950, https://doi.org/10.1074/jbc.M109.094607
10. Nazarian, J., Bouri, K. and Hoffman, E.P. (2005) Intracellular expression profiling by laser capture microdissection: three novel components of the neuromuscular junction. Physiol. Genomics 21, 70–80, https://doi.org/10.1152/physiogenomics.00227.2004
11. Becker, F., Block-Alper, L., Nakamura, G. et al. (1999) Expression of the 180-kD ribosome receptor induces membrane proliferation and increased secretory activity in yeast. J. Cell Biol. 146, 273–284, https://doi.org/10.1083/jcb.146.2.273
12. Spear, E. and Ng, D.T. (2001) The unfolded protein response: no longer just a special teams player. Traffic 2, 515–523, https://doi.org/10.1043/1600-0854.2001.20801.x
13. Hyde, M., Block-Alper, L., Felix, J. et al. (2002) Induction of secretory pathway components in yeast is associated with increased stability of their mRNA. J. Cell Biol. 156, 993–1001, https://doi.org/10.1083/jcb.200112008
14. Diefenbach, R.J., Diefenbach, E., Dougals, M.W. et al. (2004) The ribosome receptor, p180, interacts with kinesin heavy chain, KIF5B. Biochem. Biophys. Res. Commun. 319, 987–992, https://doi.org/10.1016/j.bbrc.2004.05.069
15. Krasnov, G.S., Oparina, N., Khankin, S.L. et al. (2009) Colorectal cancer 2D-proteomics: identification of altered protein expression. Mol. Biol. (Mosk) 43, 348–356
16. Pan, Y., Cao, F., Guo, A. et al. (2015) Endoplasmic reticulum ribosome-binding protein 1, RRBP1, promotes progression of colorectal cancer and predicts an unfavourable prognosis. Br. J. Cancer 113, 763–772, https://doi.org/10.1038/bjc.2015.260
17. Tsai, H.Y., Yang, Y.F., Wu, A.T. et al. (2013) Endoplasmic reticulum ribosome-binding protein 1 (RRBP1) overexpression is frequently found in lung cancer patients and alleviates intracellular stress-induced apoptosis through the enhancement of GRP78. Oncogene 32, 4921–4931, https://doi.org/10.1038/onc.2012.514
18. Telikicherla, D., Marimuthu, A., Kashyap, M.K. et al. (2012) Overexpression of ribosome binding protein 1 (RRBP1) in breast cancer. Clin. Proteomics 9, 7, https://doi.org/10.1186/1559-0275-9-7
19. Liang, X., Sun, S., Zhang, X. et al. (2015) Expression of ribosome-binding protein 1 correlates with shorter survival in Her-2 positive breast cancer. Cancer Sci. 106, 740–746, https://doi.org/10.1111/cas.12666
20. Morrow, M.W. and Brodsky, J.L. (2001) Yeast ribosomes bind to highly purified reconstituted Sec61p complex and to mammalian p180. Traffic 2, 705–716, https://doi.org/10.1043/1600-0854.2001.21005.x
21. Lee, J.C., Li, C.F., Huang, H.Y. et al. (2017) ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. J. Pathol. 241, 316–323, https://doi.org/10.1002/path.4836
22. Gao, W., Li, Q., Zhu, R. et al. (2016) La autoantigen induces ribosome binding protein 1 (RRBP1) expression through internal ribosome entry site (IRES)-mediated translation during cellular stress condition. Int. J. Mol. Sci. 17, pii: E1174, https://doi.org/10.3390/ijms17071174